Company intelligence / Profile preview
Oncolys BioPharma Inc.
Minato-ku, Tokyo, Japanoncolys.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Phase 2
01
Overview
The company has reported positive Phase I results for its lead candidate Telomelysin (OBP‑301) in advanced esophageal cancer. It continues to develop additional candidates including an epigenetic anticancer drug and a small molecule antiviral agent.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Oncolytic viruses (e.g., OBP‑301/Telomelysin)Small molecules (e.g., HDAC inhibitors)Diagnostic agents
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Medigen Biotechnology Corporation—joint development of oncolytic virus new drug OBP–301
Beyond the preview
Go deeper on Oncolys BioPharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncolys BioPharma Inc..